These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 30353392)

  • 1. ASO Author Reflections: C-Reactive Protein/Albumin Ratio as a Prognostic Factor in Patients with Malignant Pleural Mesothelioma: What Does the Novel Index Represent?
    Takamori S; Takenoyama M
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):958-959. PubMed ID: 30353392
    [No Abstract]   [Full Text] [Related]  

  • 2. The C-Reactive Protein/Albumin Ratio May Predict the Long-Term Outcome in Patients with Malignant Pleural Mesothelioma.
    Yoshida N; Baba H
    Ann Surg Oncol; 2018 Jun; 25(6):1471-1472. PubMed ID: 29516363
    [No Abstract]   [Full Text] [Related]  

  • 3. ASO Author Reflections: The C-Reactive Protein (CRP)-Albumin Ratio May Be Useful as the Most Prognostic Index Among the Immuno-nutritional Parameters Using CRP and Albumin for Resected NSCLC.
    Matsubara T; Okamoto T
    Ann Surg Oncol; 2021 Jun; 28(6):3055-3056. PubMed ID: 33095364
    [No Abstract]   [Full Text] [Related]  

  • 4. The C-Reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma: A Retrospective Multi-institutional Study.
    Takamori S; Toyokawa G; Shimokawa M; Kinoshita F; Kozuma Y; Matsubara T; Haratake N; Akamine T; Hirai F; Seto T; Tagawa T; Takenoyama M; Ichinose Y; Maehara Y
    Ann Surg Oncol; 2018 Jun; 25(6):1555-1563. PubMed ID: 29500763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ASO Author Reflections: Management of Malignant Peritoneal Mesothelioma.
    Cushman TR; Verma V; Simone CB
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):767-768. PubMed ID: 30421065
    [No Abstract]   [Full Text] [Related]  

  • 6. ASO Author Reflections: Postoperative Radiotherapy for Patients with Mesothelioma-Past, Present, and Future.
    Lewis GD; Teh BS
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):635-636. PubMed ID: 31201597
    [No Abstract]   [Full Text] [Related]  

  • 7. Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan.
    Nojiri S; Gemba K; Aoe K; Kato K; Yamaguchi T; Sato T; Kubota K; Kishimoto T
    Jpn J Clin Oncol; 2011 Jan; 41(1):32-9. PubMed ID: 20798232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis.
    Baud M; Strano S; Dechartres A; Jouni R; Triponez F; Chouaid C; Forgez P; Damotte D; Roche N; Régnard JF; Alifano M
    J Thorac Cardiovasc Surg; 2013 May; 145(5):1305-11. PubMed ID: 23072703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis.
    Ghanim B; Hoda MA; Winter MP; Klikovits T; Alimohammadi A; Hegedus B; Dome B; Grusch M; Arns M; Schenk P; Pohl W; Zielinski C; Filipits M; Klepetko W; Berger W
    Ann Surg; 2012 Aug; 256(2):357-62. PubMed ID: 22750759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma.
    Thylén A; Hjerpe A; Martensson G
    Cancer; 2001 Sep; 92(5):1224-30. PubMed ID: 11571736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.
    Nakano T; Chahinian AP; Shinjo M; Tonomura A; Miyake M; Togawa N; Ninomiya K; Higashino K
    Br J Cancer; 1998 Mar; 77(6):907-12. PubMed ID: 9528833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions.
    Kasapoglu US; Arınç S; Gungor S; Irmak I; Guney P; Aksoy F; Bandak D; Hazar A
    Clin Respir J; 2016 Nov; 10(6):791-799. PubMed ID: 25764010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated aspartate aminotransferase and monocyte counts predict unfavorable prognosis in patients with malignant pleural mesothelioma.
    Zhang A; Cao S; Jin S; Cao J; Shen J; Pan B; Zhu R; Yu Y
    Neoplasma; 2017; 64(1):114-122. PubMed ID: 27881012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma.
    Demirag F; Unsal E; Yilmaz A; Caglar A
    Chest; 2005 Nov; 128(5):3382-7. PubMed ID: 16304288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
    Cury PM; Butcher DN; Corrin B; Nicholson AG
    J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant pleural mesothelioma in Turkey, 2000-2002.
    Emri S; Demir AU
    Lung Cancer; 2004 Aug; 45 Suppl 1():S17-20. PubMed ID: 15261427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultrastructure of pleural mesothelioma and pulmonary adenocarcinoma in malignant effusions as compared with reactive mesothelial cells.
    Sakuma N; Kamei T; Ishihara T
    Acta Cytol; 1999; 43(5):777-85. PubMed ID: 10518130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Score of Long-Term Survival After Surgery for Malignant Pleural Mesothelioma: A Multicenter Analysis.
    Leuzzi G; Rea F; Spaggiari L; Marulli G; Sperduti I; Alessandrini G; Casiraghi M; Bovolato P; Pariscenti G; Alloisio M; Infante M; Pagan V; Fontana P; Oliaro A; Ruffini E; Ratto GB; Leoncini G; Sacco R; Mucilli F; Facciolo F
    Ann Thorac Surg; 2015 Sep; 100(3):890-7. PubMed ID: 26163973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions.
    Holloway AJ; Diyagama DS; Opeskin K; Creaney J; Robinson BW; Lake RA; Bowtell DD
    Clin Cancer Res; 2006 Sep; 12(17):5129-35. PubMed ID: 16951230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and prognostic factors in malignant pleural mesothelioma: a retrospective analysis of sixty-five patients.
    Tammilehto L; Maasilta P; Kostiainen S; Appelqvist P; Holsti LR; Mattson K
    Respiration; 1992; 59(3):129-35. PubMed ID: 1439223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.